Clinical Protocols trial drugs

Clinical Trial Application (CTA) has to be submitted to Health Canada seeking permission to conduct clinical trials. The submission should include information regarding drug characteristics, test data, animal studies, and clinical protocol. A clinical trial may be stopped when either it is shown to be unsafe or dramatic benefits are obtained. The approval process may be fast-tracked if a drug is shown to have substantial benefits, such as for treatment of life-threatening or severely debilitating conditions. 

PEG-1-A5P routinely enters clinical protocols) it must be clarified by randomized trials whether or not a G-phase-spedfic drug like 1-ASP interferes with... 

If a sponsor has conducted phase 1 trials outside of the United States and believes that there are adequate human safety studies already available, it may not be necessary to conduct any phase 1 trials in the United States. In such a case, the sponsor would prepare an IND and include in the initial IND submission a clinical protocol for phase 2 or 3. This IND, because it will involve exposure of more patients to the drug for the purposes of safety testing as well as efficacy evaluations, will require a greater level and depth of manufacturing and nonclinical data. The next section will describe the requirements for such an advanced-stage IND. 

Finally, the FDA is required to encourage sponsors to design open protocols for drug availability to patients not included in clinical trials. 

In most labs that perform sensitivity tests on clinical HIV isolates, the HeLa CD4+ plaque reduction assay has been replaced by the more generally useful peripheral blood mononuclear cell (PBMC)-based culture system. More than 80% of clinical isolates can be grown in PBMCs, but selection of variant strains cannot be excluded. Japour et al. (5) developed a widely used standardized protocol for drug susceptibility testing in PBMCs. This protocol can be considered the present standard and is called ACTG-DoD protocol (AIDS Clinical Trials Group, Department of Defense). It is described in Subheading 2. 

The main activities of the PMDA are to offer the pharmaceutical industry consultations with regard to clinical trial protocols and drug and medical devices development plans, to conduct new drug application review and to confirm the quality of the submitted data. The PMDA, or Drug Agency, is composed of 15 offices to conduct different services (see Figure 35.3). 

Except in the case of trials intended for trial of drug effects during pregnancy, clinical protocols should also include measures that will minimize the possibility of fetal exposure to the investigational drug. These would ordinarily include provisions for the use of a reliable method of contraception (or abstinence) for the duration of drug... 

Clinical Protocols and Investigator Information. Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks needs to be provided. In addition, information on the qualifications of clinical investigators, professionals (generally physicians) who oversee the administration of the experimental compound, to assess whether they are qualified to fulfill their clinical trial duties is needed. Finally, commitments to obtain informed consent from the research subjects, to obtain review of the study by an institutional review board (IRB), and to adhere to the investigational new drug regulations are also required. 

Improved immunotoxicity prediction during clinical drug development could be achieved within a shorter time frame. The lack of any regulatory document emphasizing the importance and need of introducing immunotoxicity in clinical trials is an obvious limitation. Insufficient knowledge and only few validated techniques available to date warrant additional research in clinical immunotoxicology. This could serve as an impetus to refine current clinical protocols that may overlook critical immune-mediated adverse effects. 

The clinical protocol determines whether the protocol will expose subjects to unnecessary risks. The protocol contains the qualifications and credentials of the investigator(s). The protocols are very detailed including the qualifications of all professionals administering the nonapproved drug product. Protocols for each phase of clinical study are required. All human research subjects must be informed of all the risks and benefits of the drug product. Informed consent must be obtained from all subjects prior to enrollment in the clinical trial. 

---